Akums Pharma placed at a vantage point in pharma growth

July 30, 2024

Akums Drugs &Pharma, a prominent contract development and manufacturing company in India, launched an ₹1,856-crore IPO with ₹680 crore in fresh issuance. Promoters reduced stakes, and proceeds will tackle debt and working capital. Generating ₹4,178 crore in FY24, Akums serves top pharma brands and stands strong in the expanding market.

More To Explore

Global Health Q2 Results: Medanta operator posts 5% rise in net profit YoY at Rs 131 crore

Global Health, which operates hospitals under the Medanta brand, on Thursday said its profit after tax increased 5 per cent to Rs 131 crore in

November 14, 2024

Glenmark Pharma Q2 Results: Co posts Rs 355 crore net profit on robust sales growth

Glenmark Pharma reported Rs 340 crore net profit in Q2FY25 led by robust sales growth in India and Europe. The drugmaker reported a net loss

November 14, 2024

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003